New approaches in identifying drugs to inactivate oncogene products

Ruiwu Liu, Ching Yi Hsieh, Kit Lam

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

With an information explosion on the molecular mechanism of oncogenesis, the completion of the human genome sequence project, and the advances in genomic and proteomic methods, many therapeutic targets for various cancers have been identified. It is timely that a number of new drug development techniques have been developed in this last decade. Candidate drug targets can now be efficiently validated with RNA interference and transgenic animals studies. Combinatorial chemistry provides large numbers of chemical compounds for drug lead discovery and optimization. High throughput assays and high content cell-based assays, in conjunction with sophisticated robotics, are now available for screening large numbers of compounds. Based on X-ray crystallographic structure data, drug leads can be discovered through in silico screening of virtual libraries. By applying these various drug discovery techniques, it is anticipated that more potent and specific anti-cancer agents will be discovered within the next decade.

Original languageEnglish (US)
Pages (from-to)13-21
Number of pages9
JournalSeminars in Cancer Biology
Volume14
Issue number1
DOIs
StatePublished - Feb 2004

Fingerprint

Oncogene Proteins
Drug Discovery
Digital Libraries
Pharmaceutical Preparations
Human Genome Project
Genetically Modified Animals
Explosions
Robotics
RNA Interference
Computer Simulation
Proteomics
Neoplasms
Carcinogenesis
X-Rays
Therapeutics

Keywords

  • Cancer therapeutic targets
  • Chemical microarrays
  • Combinatorial chemistry
  • Drug discovery
  • Inactivate oncogenes

ASJC Scopus subject areas

  • Cancer Research

Cite this

New approaches in identifying drugs to inactivate oncogene products. / Liu, Ruiwu; Hsieh, Ching Yi; Lam, Kit.

In: Seminars in Cancer Biology, Vol. 14, No. 1, 02.2004, p. 13-21.

Research output: Contribution to journalArticle

@article{eedf36edab9f469385c67f676691fa05,
title = "New approaches in identifying drugs to inactivate oncogene products",
abstract = "With an information explosion on the molecular mechanism of oncogenesis, the completion of the human genome sequence project, and the advances in genomic and proteomic methods, many therapeutic targets for various cancers have been identified. It is timely that a number of new drug development techniques have been developed in this last decade. Candidate drug targets can now be efficiently validated with RNA interference and transgenic animals studies. Combinatorial chemistry provides large numbers of chemical compounds for drug lead discovery and optimization. High throughput assays and high content cell-based assays, in conjunction with sophisticated robotics, are now available for screening large numbers of compounds. Based on X-ray crystallographic structure data, drug leads can be discovered through in silico screening of virtual libraries. By applying these various drug discovery techniques, it is anticipated that more potent and specific anti-cancer agents will be discovered within the next decade.",
keywords = "Cancer therapeutic targets, Chemical microarrays, Combinatorial chemistry, Drug discovery, Inactivate oncogenes",
author = "Ruiwu Liu and Hsieh, {Ching Yi} and Kit Lam",
year = "2004",
month = "2",
doi = "10.1016/j.semcancer.2003.11.003",
language = "English (US)",
volume = "14",
pages = "13--21",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - New approaches in identifying drugs to inactivate oncogene products

AU - Liu, Ruiwu

AU - Hsieh, Ching Yi

AU - Lam, Kit

PY - 2004/2

Y1 - 2004/2

N2 - With an information explosion on the molecular mechanism of oncogenesis, the completion of the human genome sequence project, and the advances in genomic and proteomic methods, many therapeutic targets for various cancers have been identified. It is timely that a number of new drug development techniques have been developed in this last decade. Candidate drug targets can now be efficiently validated with RNA interference and transgenic animals studies. Combinatorial chemistry provides large numbers of chemical compounds for drug lead discovery and optimization. High throughput assays and high content cell-based assays, in conjunction with sophisticated robotics, are now available for screening large numbers of compounds. Based on X-ray crystallographic structure data, drug leads can be discovered through in silico screening of virtual libraries. By applying these various drug discovery techniques, it is anticipated that more potent and specific anti-cancer agents will be discovered within the next decade.

AB - With an information explosion on the molecular mechanism of oncogenesis, the completion of the human genome sequence project, and the advances in genomic and proteomic methods, many therapeutic targets for various cancers have been identified. It is timely that a number of new drug development techniques have been developed in this last decade. Candidate drug targets can now be efficiently validated with RNA interference and transgenic animals studies. Combinatorial chemistry provides large numbers of chemical compounds for drug lead discovery and optimization. High throughput assays and high content cell-based assays, in conjunction with sophisticated robotics, are now available for screening large numbers of compounds. Based on X-ray crystallographic structure data, drug leads can be discovered through in silico screening of virtual libraries. By applying these various drug discovery techniques, it is anticipated that more potent and specific anti-cancer agents will be discovered within the next decade.

KW - Cancer therapeutic targets

KW - Chemical microarrays

KW - Combinatorial chemistry

KW - Drug discovery

KW - Inactivate oncogenes

UR - http://www.scopus.com/inward/record.url?scp=0742269699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742269699&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2003.11.003

DO - 10.1016/j.semcancer.2003.11.003

M3 - Article

C2 - 14757532

AN - SCOPUS:0742269699

VL - 14

SP - 13

EP - 21

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

IS - 1

ER -